Accredited Investors Employee Shareholders Institutions Private Companies Who We Serve Trading and InvestingData SolutionsPrivate Asset Custody Institutional TradingForge ProTrade private companies with Forge’s institutional brokerage toolBrowse CompaniesIndividual InvestingForge MarketsFind new private company investment opportunitiesForge DataAnalyze private markets via Forge’s intuitive web applicationForge Private Market IndexMonitor a benchmark for actively traded private companies Forge Accuidity Private Market IndexInvest in an institutionally-managed diversified basket of private companies (QPs only)Self-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRASolutions All InsightsPrivate Market ReportsMarket InsightsBuying and Selling Pre-IPO All ReportsPrivate Market Updates Forge Investment OutlookStartup News and TrendsPrivate Market Data and AnalyticsTech IPO Calendar for 2024Private Market ExplainedBuying Pre-IPO SharesSelling Pre-IPO Shares Glossary Videos FAQsInsights About Us Leadership Investor Relations People & Culture Careers About

Talaris Therapeutics Stock

Q: How to sell Talaris Therapeutics stock?

If you hold private company shares of Talaris Therapeutics - whether as an employee or an early investor - Forge can help you sell them. 1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have. 2. Indicate your interest to sell your Talaris Therapeutics stock on our platform. 3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.

talaristx.comHealthcare / BioTech & PharmaFounded: 1900Funding to Date: $100MM

Talaris Therapeutics is a late-clinical stage biotechnology company developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders.

Buy or sell Talaris Therapeutics stockLearn more about Talaris Therapeutics IPO

OverviewFinancingsValuation

Enterprise Value

Access Talaris Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Talaris Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Nancy Krieger MD

Chief Medical Officer

Francois Nader

Chairman

Suzanne Ildstad MD

Founder, Board Member & Chief Scientific Officer

Scott Requadt JD

Chief Executive Officer & Board Member

Board Members

Geoff MacKay

Sandip Agarwala

Longitude Capital

Mark McDade

Qiming Venture Partners

Scott Requadt JD

Suzanne Ildstad MD

Francois Nader

Nicholas Galakatos Ph.D

Blackstone Life Sciences

Talaris Therapeutics stock FAQs

Can you buy Talaris Therapeutics stock?

As Talaris Therapeutics is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private company like Talaris Therapeutics, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not an accredited investor, discover how to begin the process to potentially qualify for new investment opportunities.

How to buy Talaris Therapeutics stock?

To invest in a private company like Talaris Therapeutics through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

Create a free account to access Forge’s marketplace.
Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.

Can you sell Talaris Therapeutics stock?

Yes, you may be able to sell your Talaris Therapeutics stock, subject to certain conditions. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company's interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.

How to sell Talaris Therapeutics stock?

If you hold private company shares of - whether as an employee or an early investor - Forge can help you sell them.

Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
Indicate your interest to sell your Talaris Therapeutics stock on our platform.
Work with your dedicated Private Market Specialist who'll help guide you through every step of the transaction.

Is Talaris Therapeutics a public company?

No, Talaris Therapeutics is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.

What is Talaris Therapeutics’ stock price?

Talaris Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Talaris Therapeutics’ private market stock price with Forge Data.

What is Talaris Therapeutics’ stock ticker symbol?

Talaris Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Business Wire 04/18/2019

Talaris Therapeutics, Inc. Announces $100M Series A Financing to Advance Its Novel, Allogeneic Cell Therapy Through Late-Stage Clinical Development

The series A funding will be used to advance Talaris' proprietary, one-time, allogeneic cell therapy, FCR001, into later-stage clinical development.

FinSMEs 04/18/2019

Talaris Therapeutics Raises $100M in Series A Financing | FinSMEs

Talaris Therapeutics, which develops cell therapies with potential to eliminate chronic immunosuppression for organ transplant recipients, raised $100m

Browse More Insights

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.